Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx cuts about 20% of staff, reports Q3 revenue of $173 million and a narrower loss

Mixed Impact 4 of 5 earnings Written later

Ultragenyx reported third-quarter 2026 revenue of $173 million, up from $160 million a year earlier, and a net loss of $118 million, down from $180 million. The company also announced a restructuring that cuts about 20% of its workforce, ends the UX701 Wilson disease program, and expects about $25 million in charges in the fourth quarter. It reaffirmed its 2026 revenue guidance and its expectation of full-year GAAP profitability in 2027, and it completed the $210 million sale of a priority review voucher.

Key points

  • Q3 2026 total revenue was $173 million; net loss was $118 million, or $1.16 per share, versus $1.81 per share a year earlier
  • Restructuring expected to cost about $25 million, mostly severance, with substantially all charges in Q4 2026 and the workforce reduction substantially complete by end of 2026
  • Completed sale of the GENGLYCOS priority review voucher on October 30, 2026 for $210 million gross; 20% of proceeds payable to the NIH
  • Reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million

The filing

CompanyUltragenyx Pharmaceutical Inc. (RARE)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:07 PM ET
Accession number0001193125-26-445342

Items reported: 2.01 Acquisition or Disposition Completed2.02 Results of Operations2.05 Exit / Restructuring Costs

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.